OVID - Ovid Therapeutics Inc
IEX Last Trade
1.13
-0.070 -6.195%
Share volume: 190,991
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.20
-0.07
-5.83%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-03-13 | 2023-05-05 | 2023-08-04 | 2023-11-03 | 2024-03-08 | 2024-05-14 | |
| Assets | |||||||||
| Total Assets | 177.330 M | 165.032 M | 155.266 M | 143.367 M | 136.230 M | 125.029 M | 144.027 M | 131.611 M | |
| Current Assets | 156.081 M | 140.498 M | 131.381 M | 119.519 M | 102.171 M | 91.713 M | 109.598 M | 93.170 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.715 M | 2.640 M | 2.379 M | 1.799 M | 5.653 M | 4.642 M | 3.764 M | 2.911 M | |
| Short Term Investments | 3.715 M | 2.640 M | 2.379 M | 1.799 M | 5.653 M | 4.642 M | 3.764 M | 2.911 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 152.366 M | 137.858 M | 129.001 M | 117.720 M | 96.517 M | 87.072 M | 105.833 M | 90.259 M | |
| Total Non-current Assets | 21.249 M | 24.534 M | 23.885 M | 23.848 M | 34.059 M | 33.315 M | 34.429 M | 38.441 M | |
| Property Plant Equipment | 1.243 M | 1.160 M | 1.148 M | 1.053 M | 955.569 K | 856.491 K | 768.753 K | 686.000 K | |
| Other Assets | 15.846 M | 15.492 M | 15.184 M | 14.882 M | 14.702 M | 14.404 M | 14.104 M | 13.802 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 177.330 M | 165.032 M | 155.266 M | 143.367 M | 136.230 M | 125.029 M | 144.027 M | 131.611 M | |
| Total liabilities | 25.182 M | 22.981 M | 22.993 M | 22.419 M | 25.531 M | 23.737 M | 56.230 M | 53.333 M | |
| Total current liabilities | 9.215 M | 6.732 M | 6.992 M | 6.721 M | 10.142 M | 8.663 M | 11.474 M | 8.903 M | |
| Accounts Payable | 4.617 M | 1.033 M | 1.953 M | 1.831 M | 3.763 M | 1.217 M | 3.703 M | 3.596 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 30.000 M | 30.000 M | |
| Current long term debt | 0.000 | 0.000 | 533.946 K | 804.139 K | 944.943 K | 1.225 M | 1.246 M | 1.268 M | |
| Long term debt | 15.967 M | 16.249 M | 16.002 M | 15.698 M | 15.390 M | 15.073 M | 14.756 M | 14.430 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 30.000 M | 30.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 152.147 M | 142.051 M | 132.273 M | 120.948 M | 110.699 M | 101.292 M | 87.797 M | 78.279 M | |
| Common stock | 70.391 M | 70.431 M | 70.531 M | 70.491 M | 70.534 M | 70.619 M | 70.679 M | 70.717 M | |
| Retained earnings | -202.054 M | -214.022 M | -225.527 M | -238.883 M | -251.291 M | -262.543 M | -277.866 M | -289.560 M |